Overview of a rational approach to design type I 17β-hydroxysteroid dehydrogenase inhibitors without estrogenic activity: Chemical synthesis and biological evaluation

Journal of Steroid Biochemistry and Molecular Biology

Volumn 66, Issue 4, 1998, Pages 179-191

  Tremblay, Martin R ^a   Poirier, Donald ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; OXIDOREDUCTASE INHIBITOR; TESTOSTERONE 17BETA DEHYDROGENASE; TESTOSTERONE 17BETA DEHYDROGENASE INHIBITOR; UNCLASSIFIED DRUG;

ALKYLATION; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ESTROGEN SYNTHESIS; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION;

17-HYDROXYSTEROID DEHYDROGENASES; BREAST NEOPLASMS; DRUG DESIGN; ENZYME INHIBITORS; ESTRADIOL; FEMALE; HUMANS; KINETICS; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0031713373     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(98)00043-0     Document Type: Article

References (68)

1. Labrie F., Endocrine therapy for prostate cancer. Endocrinol. Metab. Clin. North Am. 20 (1991) 845-872.
2. Baum M., The role of endocrine therapy in primary breast cancer. J. Steroid. Biochem. 36 (1990) 187-189.
3. Von Angerer, E., The estrogen receptor as a target for rational drug design. In Molecular Biology Intelligence Unit. R. G. Landes Company, Austin, TX, 1995, 237 pp.
4. Magarian R. A., Overacre L. B., Singh S. and Meyer K. L., The medicinal chemistry of nonsteroidal antiestrogens: a review. Curr. Med. Chem. 1 (1994) 61-104.
5. Wakeling A. E., The future of new pure antiestrogens in clinical breast cancer. Breast Cancer Res. Treat. 25 (1993) 1-9.
6. Howell A., DeFriend D., Robertson J., Blamey R. and Walton P., Response to a specific antiestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 345 (1995) 29-30.
7. De Velde P. V., Nique F., Bouchoux F., Brémaud J., Hameau M.-C., Lucas D., Moratile C., Viet S., Philibert D. and Teutsch G., RU 58668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice. J. Steroid Biochem. Molec. Biol. 48 (1994) 187-196.
8. Labrie F., Intracrinology. Molec. Cell Endocr. 78 (1991) C113-C118.
9. Labrie F., Simard J., Luu-The V., Pelletier G., Belghmi K. and Bélanger A., Structure, regulation and role of 3β-hydroxysteroid dehydrogenase, 17β-hydroxysteroid dehydrogenase and aromatase enzymes in the formation of sex steroids in classical and peripheral intracrine tissues. Baillière's Clin. Endocrinol. Metab. 8 (1994) 451-474.
10. Brueggemeier R. W., Floyd E. E. and Counsell R. E., Synthesis and biochemical evaluation of inhibitors of estrogen biosynthesis. J. Med. Chem. 21 (1978) 1007-1011.
11. Evans T. R. J., Salle E. D., Ornati G., Lassus M., Benedetti M. S., Pianezolla E. and Coombies R. C., Phase I and endocrine study of exemestrane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res. 52 (1992) 5933-5939.
12. Iveson T. J., Smith I. E., Ahern J., Smithers D. A., Trunet P. F. and Dowsett M., Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J. Clin. Endocrinol. Metab. 77 (1993) 324-331.
13. Brodie A. M. H., Aromatase inhibitors in the treatment of breast cancer. J. Steroid. Biochem. Molec. Biol. 48 (1994) 281-287.
14. Brueggemeier R. W., Aromatase inhibitors-mechanisms of steroidal inhibitors. Breast Cancer Res. Treat. 30 (1994) 31-42.
15. Johnston S. R., Smith I. E., Doody D., Jacobs S., Robertshaw H. and Dowsett M., Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. Cancer Res. 54 (1994) 5875-5881.
16. Dowsett M. and Coombes R. C., Second generation aromatase inhibitor-4-hydroxyandrostenedione. Breast Cancer Res. Treat. 30 (1994) 81-87.
17. Bajetta E., Zilembo N., Buzzoni R., Noberasco C., Martinetti A., Ferrari L., Bartoli C., Sacchini V., Attili A. and Lepera P., Formestane: effective therapy in postmenopausal women with advanced breast cancer. Ann. Oncol. 5 (Suppl. 7) (1994) S15-S17.
18. Wouters W., Snoeck E. and De Coster R., Vorozole, a specific nonsteroidal aromatase inhibitor. Breast Cancer Res. Treat. 30 (1994) 89-94.
19. Plourde P. V., Dyroff M., Dowsett M., Demers L., Yates R. and Webster A., ARIMIDEX: a new oral, once-a-day aromatase inhibitor. J. Steroid Biochem. Mol. Biol. 53 (1995) 175-179.
20. Bonnefoi H. R., Smith I. E., Dowsett M., Trunet P. F., Houston S. J., Da Luz R. J., Rubens R. D., Coombes R. C. and Powles T. J., Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer. Br. J. Cancer 73 (1996) 539-542.
21. Harvey H. A., Aromatase inhibitors in clinical practice: current status and a look to the future. Semin. Oncol. 23 (1996) 33-38.
22. Martel C., Rhéaume E., Takahashi M., Trudel C., Couët J., Luu-The V., Simard J. and Labrie F., Distribution of 17β-hydroxysteroid dehydrogenase gene expression and activity in rat and human tissues. J. Steroid Biochem. Molec. Biol. 41 (1992) 597-603.
23. Santner S. J., Feil P. D. and Santen R. J., In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J. Clin. Endocrinol. Metab. 59 (1984) 29-33.
24. Poutanen M., Isomaa V., Peltoketo H. and Vihko R., Role of 17β-hydroxysteroid dehydrogenase type I in endocrine and intracrine estradiol biosynthesis. J. Steroid. Biochem. Molec. Biol. 55 (1995) 525-532.
25. Labrie F., Luu-The V., Lin S.-X., Labrie C., Simard J., Breton R. and Bélanger A., The key role of 17β-hydroxysteroid dehydrogenase in sex steroid biology. Steroids 62 (1997) 148-158.
26. Luu-The V., Labrie C., Zhao H.-R., Couët J., Lachance Y., Simard J., Leblanc G., Côté J., Bérubé D., Gagné R. and Labrie F., Characterization of cDNAs for human estradiol 17β-hydroxysteroid dehydrogenase and assignment of the gene to chromosome 17: evidence of two mRNA species with distinct 5′-termini in human placenta. Mol. Endocrinol. 3 (1989) 1301-1309.
27. Wu L., Einstein M., Geissler W. M., Chan H. K., Elliston K. O. and Anderson S., Expression cloning and characterization of human 17β-hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20α-hydroxysteroid dehydrogenase activity. J. Biol. Chem. 268 (1993) 12964-12969.
28. Geissler W. M., Davis D. L., Wu L., Bradshaw K. D., Sushma P., Mendonca B. B., Elliston K. O., Wilson J. D., Russel D. W. and Andersson S., Male pseudohermaphroditism caused by mutations of testicular 17β-hydroxysteroid dehydrogenase 3. Nature Genet. 7 (1994) 34-39.
29. Adamski J., Normand T., Leenders F., Monté D., Begue A., Stéhelin D., JungbIut P. W. and De Launoit Y., Molecular cloning of a novel widely expressed human 80 kDa 17β-hydroxysteroid dehydrogenase IV. Biochem. J. 311 (1995) 437-443.
30. Zhang, Y., Dufort, I., Soucy, P., Labrie, F. and Luu-The, V., Cloning and expression of human type V 17β-hydroxysteroid dehydrogenase [abstract P3-614]. Proceedings of the 77th Annual Meeting of the Endocrine Society, Washington, DC, Bethesda, MD, The Endrocrine Society, p. 622.
31. Blomquist C. H., Kinetic analysis of enzymic activities: prediction of multiple forms of 17β-hydroxysteroid dehydrogenase. J. Steroid Biochem. Molec. Biol. 55 (1995) 515-524.
32. Blomquist C. H., Lindemann N. J. and Hakanson E. Y., 17β-hydroxysteroid and 20α-hydroxysteroid dehydrogenase activities of human placental microsomes: kinetics evidence for two enzymes differing in substrate specificity. Arch. Biochem. Biophys. 239 (1985) 206-215.
33. Penning T. M., 17β-Hydroxysteroid dehydrogenase: inhibitors and inhibitor design. Endocrine-related cancer 3 (1996) 41-56.
34. Chin C. C. and Warren J. C., Synthesis of 16α-bromoacetoxyestradiol 3-methyl ether and study of the binding site of human placental estradiol 17β-dehydrogenase. J. Biol. Chem. 250 (1975) 7682-7686.
35. Bhatnagar Y. M., Chin C. C. and Warren J. C., Synthesis of 4-bromoacetamidoestrone methyl ether and study of steroid binding site of human placental estradiol 17β-dehydrogenase. J. Biol. Chem. 253 (1978) 811-815.
36. Inano H. and Engel L. L., Photoaffinity labeling of human placental estradiol dehydrogenase with 3-(arylazido-β-alanine). J. Biol Chem. 255 (1980) 7694-7699.
37. Chin C. C., Asmar P. and Warren J. C., Synthesis of 2-bromoacetamidoestrone methyl ether and study of steroid-binding site of human placental estradiol 17β-dehydrogenase. J. Biol. Chem. 255 (1980) 3660-3664.
38. Strickler R. C., Tobas B. and Covey D. R., Human placental 17β-estradiol dehydrogenase and 20α-hydroxysteroid dehydrogenase. J. Biol. Chem. 256 (1981) 316-321.
39. Thomas J. L., Asibey-Berko E. and Strickler R. C., The affinity alkylators 11α-bromoacetoxyprogesterone and estrone 3-bromoacetate, modify a common histidyl residue in the active site of human placental 17β,20α-hydroxysteroid dehydrogenase. J. Steroid Biochem. 25 (1986) 203-208.
40. Murdock G. L., Warren J. C. and Sweet F., Human placental estradiol 17β-dehydrogenase: Evidence for inverted substrate orientation (wrong-way binding) at the active site. Biochemistry 27 (1988) 4452-4458.
41. Thomas J. L., LaRochelle M. C., Covey D. F. and Strickler R. C., Inactivation of human placental 17β,20α-hydroxysteroid dehydrogenase by 16-methylene estrone, as affinity alkylator enzymatically generated from 16-methylene estradiol. J. Biol. Chem. 258 (1983) 11500-11504.
42. Auchus R. J. and Covey D. F., Mechanism-based inactivation of 17β,20α-hydroxysteroid dehydrogenase by an acetylenic secoestradiol. Biochemistry 25 (1986) 7295-7300.
43. Inano H. and Tamaoki B., Affinity labelling of arginyl residues at the catalytic region of estradiol 17β-hydroxysteroid dehydrogenase from human placenta by 16-oxo-estrone. Eur. J. Biochem. 129 (1983) 691-695.
44. Sweet F., Boyd J., Medina O., Konderski L. and Murdock G. L., Hydrogen bonding in steroidogenesis: studies on new heterocyclic analogs of estrone that inhibit human estradiol 17β-dehydrogenase. Biochim. Biophys. Commun. 180 (1991) 1057-1063.
45. Labrie C., Martel C., Dufour J.-M., Lévesque G., Mérand Y. and Labrie F., Novel compounds inhibit estrogen formation and action. Cancer Res. 52 (1992) 610-615.
46. Luu-The V., Zhang Y., Poirier D. and Labrie F., Characteristics of human types 1, 2 and 3 17β-hydroxysteroid dehydrogenase activities: oxidation/reduction and inhibition. J. Steroid Biochem. Molec. Biol. 55 (1995) 581-587.
47. Sam, K.-M., Boivin, R. P., Tremblay, M. R., Auger, S. and Poirier, D., C16 and C17 derivatives of estradiol as inhibitors of 17β-hydroxysteroid dehydrogenase type I: chemical synthesis and structure-activity relationships. Drug Design Discov., 1997 (in press).
48. Fevig T. L. and Katzenellenbogen J. A., A short, stereoselective route to 16α-(substituted-alkyl)-estradiol derivatives. J. Org. Chem. 52 (1987) 247-251.
49. Sam K.-M., Boivin R. P., Auger S. and Poirier D., 16α-propyl derivatives of estradiol as inhibitors of 17β-hydroxysteroid dehydrogenase type I. Bioorg. Med. Chem. Lett. 4 (1994) 2129-2132.
50. Tremblay M. R., Auger S. and Poirier D., A convenient synthetic method for alpha-alkylation of steroidal 17-ketone: preparation of 16β-(THPO-heptyl)-estradiol. Synth. Commun. 25 (1995) 2483-2495.
51. Tremblay M. R., Auger S. and Poirier D., Synthesis of 16-(bromoalkyl)-estradiols having inhibitory effect on human placental estradiol 17β-hydroxysteroid dehydrogenase (17β-HSD type I). Bioorg. Med. Chem. 3 (1995) 505-523.
52. Blomquist C. H., Leung B. S., Beaudoin C., Poirier D. and Tremblay Y., Intracellular regulation of 17β-hydroxysteroid dehydrogenase type 2 catalytic activity in A431 cells. J. Endocrinology 153 (1997) 453-464.
53. Fevig T. L., Mao M. K. and Katzenellenbogen J. A., Estrogen receptor binding tolerance of 16α-substituted estradiol derivatives. Steroids 51 (1988) 471-497.
54. Wakeling A. E. and Bowler J., Steroidal pure antiestrogens. Endocrinology 112 (1987) R7-R10.
55. Lévesque C., Mérand Y., Dufour J.-M., Labrie C. and Labrie F., Synthesis and biological activity of new halo-steroidal antiestrogens. J. Med. Chem. 34 (1991) 1624-1630.
56. Santner S. J. and Santen R. J., Inhibition of estrone sulfatase and 17β-hydroxysteroid dehydrogenase by antiestrogens. J. Steroid Biochem. Molec. Biol. 45 (1993) 383-390.
57. Pelletier J. D., Labrie F. and Poirier D., N-butyl, N-methyl 11-[3′,17′β (dihydroxy)-1′,3′,5′(10′)-estratrien-16′α- yl]-9 (R/S)-bromoundecanamide: synthesis and 17β-HSD inhibiting, estrogenic and antiestrogenic activities. Steroids 59 (1994) 536-547.
58. Pelletier J. D. and Poirier D., Synthesis and evaluation of estradiol derivatives with 16α-(bromoalkylamide), 16α-(bromoalkyl) or 16α-(bromoalkynyl) side chain as inhibitors of 17β-hydroxysteroid dehydrogenase type I without estrogenic activity. Bioorg. Med. Chem. 4 (1996) 1617-1628.
59. Tremblay M. R. and Poirier D., Synthesis of 16-[carbamoyl-(bromomethyl) alkyl]estradiol: a potential dual-action inhibitor designed to blockade estrogen action and biosynthesis. J. Chem. Soc. Perkin Trans. 1 22 (1996) 2765-2771.
60. Arbuckle N. D., Dauvois S. and Parker M. G., Effects of antiestrogens on the DNA binding activity of estrogen receptors in vitro. Nucleic Acids Res. 20 (1992) 3839-3844.
61. Poirier D., Dionne P. and Auger S., A 6β-(thiaheptanamide) derivative of estradiol as inhibitor of 17β-hydroxysteroid dehydrogenase type I. J. Steroid Biochem. Molec. Biol. 64 (1998) 83-90.
62. Poirier D., Labrie C., Mérand Y. and Labrie F., Synthesis and biological activity of 17α-alkylamide derivatives of estradiol. J. Steroid Biochem. Molec. Biol. 38 (1991) 759-774.
63. Poirier D., Mérand Y., Labrie C. and Labrie F., D-ring alkylamide derivatives of estradiol: effect on ER-binding affinity and antiestrogenic activity. Bioorg. Med. Chem. Lett. 6 (1996) 2537-2542.
64. Ghosh D., Pletnev V. Z., Zhu D.-W., Wawrzak Z., Duax W. L., Pangborn W., Labrie F. and Lin S.-X., Structure of human estrogenic 17β-hydroxysteroid dehydrogenase at 2.20 A resolution. Structure 3 (1995) 503-513.
65. Azzi A., Rehse P., Zhu D.-W., Campbell R. L., Labrie F. and Lin S.-X., Crystal structure of human estrogenic 17β-hydroxysteroid dehydrogenase complexed with 17β-estradiol. Nature Struct. Biol. 3 (1996) 665-668.
66. Breton R., Housset D., Mazza C. and Frontecilla-Camps J. C., The structure of a complex of human 17β-hydroxysteroid dehydrogenase with estradiol and NADP identifies two principal targets for the design of inhibitors. Structure 4 (1996) 905-915.
67. Anstead G. M., Carlson K. E. and Katzenellenbogen J. A., The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 62 (1997) 268-303.
68. Schwabe J. W. R., Chapman L., Finch J. T., Rhodes D. and Nenhaus D., DNA recognition by the oestrogen receptor: from solution to the crystal. Structure 1 (1993) 187-204.